Overview
This is harder to answer than it looks, and the reason is worth naming: desire is a subjective endpoint that people are poor at recalling accurately after the fact.
Ask someone a month later whether their libido improved and the answer is shaped by mood, by how the month went, by what they hoped for, and by how much they spent. That is not a criticism of anyone — it is a known problem in assessing every treatment with a subjective outcome, and it is why the trials in this area use structured measures rather than asking.
| What to track | Why it works better than recall |
|---|---|
| Number of satisfying encounters | Countable, not a judgment. A primary trial endpoint |
| Whether desire arose spontaneously | Distinguishes wanting from responding to a partner |
| Distress about the situation | The endpoint that matters most. Also a trial measure |
| Whether nausea or side effects limited use | The most common reason for stopping — track it separately |
| What else changed that month | Sleep, stress, mood, relationship — the confounders |
The practical method: decide before you start what you are looking for and how you will count it, keep a simple record as you go, and review at an agreed point. Anything less than that and you are comparing a memory against a hope.
What the trials actually measured
Worth knowing, because it tells you which questions are answerable.
The pivotal studies used validated instruments rather than a general question about libido — a desire domain score from a standardized sexual function questionnaire, and a distress score measuring how bothered participants were by their situation.
The results were statistically significant and modest in magnitude. Some participants improved clearly. Many did not improve meaningfully. The average effect was real and it was not dramatic.
That matters for how you assess your own experience. A modest average effect means a range: for some people it does something noticeable, for others nothing, and there is currently no way to predict which you will be before trying.
Note also who was studied: the trials were in premenopausal women with acquired, generalized hypoactive sexual desire disorder, which is also the approved indication. Use outside that population is off-label and the trial results do not directly transfer to it. More on that.
Distress is the endpoint that matters
This is the most useful reframe available here.
A lower frequency of desire is only a problem if it is a problem to you. Plenty of people have less interest in sex in midlife and are entirely untroubled by it — that is not a condition and it does not need treating.
The clinical definition of hypoactive sexual desire disorder requires associated distress, and the trials measured distress reduction as a co-primary endpoint for exactly this reason.
So the honest question at review is not "has my libido gone up." It is: is the thing that was bothering me bothering me less. That is a better question, it is easier to answer truthfully, and it is what treatment is actually for.
What to count, and how
Keep it simple enough that you will actually do it.
A short note after each occasion of use. Did desire arise, did anything happen, how was the experience, and did side effects interfere. Four brief entries, not a diary.
A count over the period — how many satisfying encounters, compared with a comparable period before.
A distress check at the start and at the review, rating how much the situation bothers you. Same question both times.
A note of confounders. A stressful month at work, poor sleep, a relationship strain or a new medication will all move these numbers, and knowing about them prevents attributing a bad month to a treatment failure or a good one to the drug.
The point of writing it down is that you cannot reconstruct it afterwards. Memory for this is genuinely unreliable.
When to conclude it is not working
A defined review point rather than an open-ended arrangement, and the honest possibilities at that point are these.
No change across several uses. Then it is reasonable to stop, and to look again at what else might be driving the problem.
Side effects limiting use. Nausea is the most common reason people discontinue, and if it is preventing you from using the treatment as intended, the treatment is not workable for you regardless of whether it would otherwise help.
Something changed but not the thing that mattered. Worth unpicking — it may point at a different intervention.
Improvement, and it is worth continuing. Also a real outcome, and a review is what establishes it rather than assumes it.
What we would not do is continue indefinitely without an assessment, or increase intensity because nothing happened. If a defined trial produced nothing, more of it is not the obvious next step.
What to revisit if it did not help
Most of the causes of low desire in midlife are not addressed by this medication, and if a trial came back empty, they are where to look.
Pain or discomfort with sex, the most common and most treatable cause in midlife women, and the one that most often turns out to be the whole answer. Local treatment for it.
Medication — SSRIs, SNRIs, beta blockers, opioids and others.
Sleep, fatigue and mood, all of which affect desire directly and none of which respond to a desire medication.
Thyroid, ferritin and prolactin.
Relationship and situational context.
The whole list, in the order it usually matters.
Frequently asked questions
How do I know if PT-141 is working? By deciding in advance what you are measuring — satisfying encounters, whether desire arose, and how distressed you are by the situation — recording it as you go, and reviewing at an agreed point.
How many times should I try it before deciding? That is a conversation to have when it is prescribed, so that the review point is agreed rather than improvised. What matters is that there is one.
Is it normal to feel nothing? The trial effects were modest on average, which means a range of individual responses including no response. It is a common outcome.
Should I try more if it is not working? No. If a defined trial produced nothing, increasing it is not the answer — reassessing what is driving the problem is.
What if the nausea is the problem? Then the treatment is not workable for you as intended, and that is worth saying plainly at review rather than persisting.
Where this fits in your plan
The thing that makes a trial of any desire medication useful is deciding what success looks like before you start, and being willing to call it either way at the end.
That is how we set them up — an agreed measure, an agreed review point, and an honest conversation about what to do next. What we check first, and what treatment involves.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
